Yet, achieving pCR is a major treatment goal in its own right since this outcome is associated with prolonged event-free and overall survival.23 For this reason, the NCCN also advises consideration of NT for HER2+ cT1c breast cancers.2 Unfortunately, data to guide these treatment decisions are sparse. The gene discussed is ERBB2; the disease is breast carcinoma.